Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.